^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ETBX-011

    i
    Associations
    News

    Trials

    Company:
    ImmunityBio
    Drug class:
    Immunostimulant, CEA inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (NCT03387085)
    Phase 1/2
    ImmunityBio, Inc.
    Active, not recruiting
    Last update posted :
    09/27/2023
    Initiation :
    03/16/2018
    Primary completion :
    09/01/2023
    Completion :
    10/01/2023
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification • PGR expression
    |
    Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer (NCT03384316)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/09/2020
    Initiation :
    01/31/2018
    Primary completion :
    05/22/2018
    Completion :
    08/24/2020
    CEACAM5
    |
    ETBX-011 • ETBX-051 • ETBX-061